We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Acorda, Spectrum Receive FDA Rebuke over Misleading Print Materials
Acorda, Spectrum Receive FDA Rebuke over Misleading Print Materials
August 1, 2013
Acorda Therapeutics and Spectrum Pharmaceuticals each received FDA enforcement letters late last month blasting the drugmakers for print materials the agency says minimize, and in the case of Acorda, ignore risk information altogether.